Clinical Trials Logo

Acute Lung Injury clinical trials

View clinical trials related to Acute Lung Injury.

Filter by:

NCT ID: NCT03368092 Recruiting - Clinical trials for Respiratory Distress Syndrome, Adult

Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma

TRAUMADORNASE
Start date: March 4, 2019
Phase: Phase 3
Study type: Interventional

Severe hypoxemia following trauma may happen in many circumstances (aspiration, ventilation-associated pneumonia, lung contusion...), most of which are not exclusively associated with a direct injury to the lungs. Severe trauma and associated musculoskeletal injuries result in the acute release of Damage-Associated Molecular Patterns (DAMPs) in plasma, many of which are made of nucleic acids. DAMPs then bind leukocytes and trigger NETosis (Neutrophil Extracellular Traps), the release of nuclear material coated with proteolytic enzymes, which ultimately promotes remote lung injury and acute respiratory distress syndrome (ARDS). Considering that many DAMPs and all NETs are made of nucleic acids, we hypothesize that dornase alfa, a commercially available recombinant desoxyribonuclease (DNAse) could reduce DAMPs and NETs-induced lung injury in severe trauma patients under mechanical ventilation in the intensive care unit (ICU). The primary objective is to demonstrate a reduction in the incidence of moderate to severe ARDS in severe trauma patients during the first seven ICU days from 45% to 30% by providing aerosolized dornase alfa once during the first two consecutive ICU days and compared to equivalent provision of placebo (NaCl 0,9%). The secondary objectives are to demonstrate, by using aerosolized dornase alfa compared to placebo: - an improvement in static lung compliance - a reduction in mechanical ventilation duration / an increase in ventilation-free ICU days - a reduction in the length of ICU stay - a reduction in the hospital length of stay - a reduction in multi-organ failure - a reduction in ventilator-associated pneumonia (VAP) - a reduction in mortality at day 28

NCT ID: NCT03296059 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome (ARDS)

Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates

Start date: October 1, 2017
Phase: N/A
Study type: Interventional

Acute respiratory distress syndrome (ARDS) in neonates has been defined in 2017. The death rate is over 50%.There are no special treatments for acute respiratory distress syndrome.

NCT ID: NCT03281473 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Comparison of Positive End Expiratory Pressure Titration Methods in ARDS Patients

ELSE
Start date: October 2, 2018
Phase: N/A
Study type: Interventional

This study aims at assessing the short-term physiological effects of 2 positive end expiratory pressure titration strategies in patients with ARDS.

NCT ID: NCT03236272 Recruiting - Clinical trials for Respiratory Distress Syndrome, Adult

Establishment of a Biomarkers-based Early Warning System of Acute Respiratory Distress Syndrome (ARDS)

Start date: September 15, 2017
Phase:
Study type: Observational

The aim of the investigators 'study is to investigate the relationship between the biomarkers (e.g. protein markers, genetic polymorphisms and epigenetic markers) and the onset of ARDS. In this study, the participants were divided into case group (with ARDS) and control group (without ARDS), based on a nested case-control study method. During the diagnosis and treatment, the clinical data of subjects are collected at the given time point. And the clinical data are extracted from plasma, blood and bronchoalveolar lavage fluid of participants. These data will be analyzed based on statistical methods. In the end ,the investigators can build a multi index early warning model based on the biomarkers,which is meaningful for the early diagnosis of the patient with high-risk for ARDS and provide evidence for the early treatment.

NCT ID: NCT03227289 Recruiting - ARDS Clinical Trials

Acute Respiratory Distress Syndrome(ARDS) in Neonates

Start date: August 1, 2015
Phase:
Study type: Observational

Acute respiratory distress syndrome in neonates has been defined in 2015. Earlier identification and successful intervention into the potential pregnancy associated risk factors for the conversion from NRDS to ARDS is one of the most important components of ARDS prevention.

NCT ID: NCT03217162 Recruiting - ARDS Clinical Trials

Surfactant for Neonate With Acute Respiratory Distress Syndrome (ARDS)

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Acute respiratory distress syndrome (ARDS) in neonates has been defined, the role of surfactant is not clear. This study aimed to determine whether ARDS neonate would benefit from surfactant when oxygenation deteriorated on mechanical ventilation and to identify any potential risk factors related to mortality.

NCT ID: NCT03217149 Recruiting - ARDS Clinical Trials

Heliox for Neonate With Acute Respiratory Distress Syndrome (ARDS)

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Acute respiratory distress syndrome (ARDS) in neonates has been defined, the role of heliox is not clear.This study aimed to determine whether ARDS neonate would benefit from heliox when oxygenation deteriorated on mechanical ventilation and to identify any potential risk factors related to mortality.

NCT ID: NCT03202641 Recruiting - Clinical trials for Mechanical Ventilation Complication

Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients

Start date: June 19, 2019
Phase: N/A
Study type: Interventional

The goal of this interventional crossover study, in intubated and mechanically ventilated Acute Respiratory Distress Syndrome (ARDS) patients, is to compare two positive end-expiratory pressure (PEEP) titration techniques regarding: respiratory mechanics, gas exchange, changes in aeration, ventilation/perfusion matching its impact on cardiac function, especially the right heart (RH). The PEEP titration techniques are: PEEP selection based on low PEEP/high FiO2 table ("PEEPARDSnet") and lung recruitment maneuver (LRM) plus PEEPdec titration based on the best compliance of the respiratory system("PEEPLRM").

NCT ID: NCT03076450 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Evaluation of POC Lung Ultrasound Combined With Pressure-volume Curve to Titration Adjust PEEP for ARDS Lung Recruitment

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

Using lung ultrasound re-aeration score(LUS-RAS) combined with pressure-volume curve(PVC) adjust maintain positive end-expiratory pressure(PEEP) after recruitment maneuver, to achieve real-time adjustment, reduce ventilation-associated lung injury and the purpose of effective lung recruitment.

NCT ID: NCT03042143 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST)

REALIST
Start date: January 7, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Acute Respiratory Distress Syndrome (ARDS) causes the lungs to fail due to the collection of fluid in the lungs (pulmonary oedema). ARDS is common in severely ill patients in Intensive Care Units and is associated with a high mortality and a high morbidity in those who survive. ARDS occurs in approximately 20% case of COVID-19 and respiratory failure is the leading cause of mortality. There is a large economic burden with direct healthcare costs, but also indirectly due to the impact on the carer and patient through the patients inability to return to full time employment. There is little evidence for effective drug (pharmacological) treatment for ARDS. There is increasing information that mesenchymal stem cells (MSCs) might be important in treating ARDS. REALIST will investigate if a single infusion of MSCs will help in the treatment of ARDS. The first step will be to first of all determine what dose of MSCs is safe and then divide patients suffering from ARDS into two groups, one of which will get MSCs and the other a harmless dummy (or placebo) infusion, who will then be followed up to determine if lung function improves. If effective this may lead to further research to determine if MSCs are effective in patients with ARDS.